Press Releases
Browse the the latest press releases from around the industry. Want to filter press releases by date, keyword, and more? Search here.
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients - - Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than previously published real-world data for pom-refractory, bispecific or anti-BCMA exposed patients -